Arizona Tribune - Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile

As part of the study, mice implanted with colorectal cancer tumours (HCT116/PTEN+/+ tumours) were divided into three groups and received three separate injections over a 24-day period. Treatment groups included those receiving empty nanoparticles, empty nanoparticles with radiation, and PNKP inhibitor-loaded nanoparticles with radiation. Throughout the study, no significant signs of toxicity such as weight loss were detected in any group, including those treated with the nanoparticle formulation of the PNKP inhibitor in conjunction with radiation. [2]

A key factor in developing safer and more effective cancer treatments is ensuring a low toxicity profile. Onco's Technology has demonstrated minimal toxicity in preclinical animal models, which suggests its potential for use in advancing therapies that cause fewer side effects. In compliance with Health Canada regulations, drugs must undergo rigorous testing in both animal models (in vivo) and cell cultures (in vitro) to assess their safety and toxicity at doses aimed at achieving therapeutic effects.

"Establishing the safety of combination therapies is an important step in advancing cancer treatment. The findings from this study reinforce the strong safety profile of our PNKP technology in animal testing when used alongside radiation therapy. With low toxicity being a key factor in treatment development, these results provide a solid foundation for future research as we continue exploring the potential of this approach in upcoming studies," said Thomas O'Shaughnessy, CEO of the Company.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

[1] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920

[2] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

P.Hernandez--AT